Literature DB >> 20972658

Impaired striatal dopamine output of homozygous Wfs1 mutant mice in response to [K+] challenge.

Vallo Matto1, Anton Terasmaa, Eero Vasar, Sulev Kõks.   

Abstract

Loss of function of the Wfs1 gene causes Wolfram syndrome, a rare multisystem degenerative disorder. Mutant mice with targeted Wfs1 gene disruption (Wfs1 KO) display morphological and behavioral impairments that are not well understood. The present study aimed to investigate the striatal dopamine output of wild-type, heterozygous, and homozygous Wfs1 null-mutant mice using in vivo microdialysis technique. The baseline dopamine output in striatum was similar in all three animal groups. The application of 100 mM [K+]-rich modified Ringer solution caused in homozygous Wfs1 mutant mice an increase of dopamine output by 400%, while in wild-type and heterozygous animals, the increase of the dopamine output yielded up to 1,200%. In sum, the homozygous Wfs1 mutant mice (AUC₀₋₃ = 0.212 nM/μl h) show significantly decreased striatal dopamine output in response to high-concentration [K+] challenge as compared with wild-type or heterozygous Wfs1 mutant conspecifics (AUC₀₋₃ = 0.427 and 0.505 nM/μl h, respectively). This could explain at least some of the behavioral alterations in Wfs1 mutant mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20972658     DOI: 10.1007/s13105-010-0048-0

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  27 in total

Review 1.  Analysis of biogenic amines in microdialysates of the brain.

Authors:  B H Westerink
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-09-29

2.  WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic beta-cells.

Authors:  Takahiro Yamada; Hisamitsu Ishihara; Akira Tamura; Rui Takahashi; Suguru Yamaguchi; Daisuke Takei; Ai Tokita; Chihiro Satake; Fumi Tashiro; Hideki Katagiri; Hiroyuki Aburatani; Jun-ichi Miyazaki; Yoshitomo Oka
Journal:  Hum Mol Genet       Date:  2006-03-28       Impact factor: 6.150

3.  Effects of voltage-sensitive calcium channel blockers on extracellular dopamine levels in rat striatum.

Authors:  A El Ayadi; I Afailal; M Errami
Journal:  Metab Brain Dis       Date:  2001-12       Impact factor: 3.584

Review 4.  Voltage-dependent K(+) channels in pancreatic beta cells: role, regulation and potential as therapeutic targets.

Authors:  P E MacDonald; M B Wheeler
Journal:  Diabetologia       Date:  2003-06-27       Impact factor: 10.122

5.  Wfs1 gene deletion causes growth retardation in mice and interferes with the growth hormone pathway.

Authors:  S Kõks; U Soomets; J L Paya-Cano; C Fernandes; H Luuk; M Plaas; A Terasmaa; V Tillmann; K Noormets; E Vasar; L C Schalkwyk
Journal:  Physiol Genomics       Date:  2009-03-17       Impact factor: 3.107

6.  Behavioral and gene expression analyses of Wfs1 knockout mice as a possible animal model of mood disorder.

Authors:  Tadafumi Kato; Mizuho Ishiwata; Kazuyuki Yamada; Takaoki Kasahara; Chihiro Kakiuchi; Kazuya Iwamoto; Koki Kawamura; Hisamitsu Ishihara; Yoshitomo Oka
Journal:  Neurosci Res       Date:  2008-02-14       Impact factor: 3.304

7.  Alteration of methamphetamine-induced striatal dopamine release in mint-1 knockout mice.

Authors:  Atsushi Mori; Keiji Okuyama; Masato Horie; Yoshihiro Taniguchi; Takashi Wadatsu; Naoki Nishino; Yoshikazu Shimada; Norihiro Miyazawa; Satoshi Takeda; Masashi Niimi; Hiroyuki Kyushiki; Mari Kondo; Yasuhide Mitsumoto
Journal:  Neurosci Res       Date:  2002-07       Impact factor: 3.304

8.  Kir6.2 knockout alters neurotransmitter release in mouse striatum: an in vivo microdialysis study.

Authors:  Xue-Ru Shi; Jing Chang; Jian-Hua Ding; Yi Fan; Xiu-Lan Sun; Gang Hu
Journal:  Neurosci Lett       Date:  2008-05-14       Impact factor: 3.046

9.  Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein.

Authors:  T M Strom; K Hörtnagel; S Hofmann; F Gekeler; C Scharfe; W Rabl; K D Gerbitz; T Meitinger
Journal:  Hum Mol Genet       Date:  1998-12       Impact factor: 6.150

10.  Genetically programmed selective islet beta-cell loss in diabetic subjects with Wolfram's syndrome.

Authors:  A Karasik; C O'Hara; S Srikanta; M Swift; J S Soeldner; C R Kahn; R D Herskowitz
Journal:  Diabetes Care       Date:  1989-02       Impact factor: 19.112

View more
  4 in total

1.  Wfs1 mutation makes mice sensitive to insulin-like effect of acute valproic acid and resistant to streptozocin.

Authors:  Anton Terasmaa; Ursel Soomets; Julia Oflijan; Marite Punapart; Mats Hansen; Vallo Matto; Kersti Ehrlich; Anne Must; Sulev Kõks; Eero Vasar
Journal:  J Physiol Biochem       Date:  2011-04-02       Impact factor: 4.158

2.  Activation of the sigma-1 receptor chaperone alleviates symptoms of Wolfram syndrome in preclinical models.

Authors:  Lucie Crouzier; Alberto Danese; Yuko Yasui; Elodie M Richard; Jean-Charles Liévens; Simone Patergnani; Simon Couly; Camille Diez; Morgane Denus; Nicolas Cubedo; Mireille Rossel; Marc Thiry; Tsung-Ping Su; Paolo Pinton; Tangui Maurice; Benjamin Delprat
Journal:  Sci Transl Med       Date:  2022-02-09       Impact factor: 19.319

3.  Wfs1 is expressed in dopaminoceptive regions of the amniote brain and modulates levels of D1-like receptors.

Authors:  Triin Tekko; Triin Lakspere; Anni Allikalt; Jaanus End; Karl Rene Kõlvart; Toomas Jagomäe; Anton Terasmaa; Mari-Anne Philips; Tanel Visnapuu; Fred Väärtnõu; Scott F Gilbert; Ago Rinken; Eero Vasar; Kersti Lilleväli
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

4.  Wfs1-deficient mice display altered function of serotonergic system and increased behavioral response to antidepressants.

Authors:  Tanel Visnapuu; Sirli Raud; Maarja Loomets; Riin Reimets; Silva Sütt; Hendrik Luuk; Mario Plaas; Sulev Kõks; Vallo Volke; Aet Alttoa; Jaanus Harro; Eero Vasar
Journal:  Front Neurosci       Date:  2013-07-31       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.